Syncona has invested a further £19.9m in Purespring Therapeutics as part of an £80m oversubscribed Series B financing for that company. Syncona formed part of a leading Series B syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient Capital. Syncona founded Purespring in 2020 as one of the first adeno-associated virus … Continue reading Syncona commits another £19.9m to Purespring Therapeutics